Humalog Mix 50/50 Kwikpen

Diabetes mellitus

Administer within 15 minutes before a meal or immediately after a meal by injection into the subcutaneous tissue of the abdominal wall, thigh, upper arm, or buttocks. To reduce the risk of lipodystrophy, rotate the injection site within the same region from one injection to the next.

Subcutaneous Type 1 diabetes mellitus Approximately one third of the total daily insulin requirements SC; rapid-acting or short-acting, premeal insulin should be used to satisfy the remainder of the daily insulin requirements Usual daily maintenance range is 0.5-1 unit/kg/day in divided doses; nonobese may require 0.4-0.6 unit/kg/day; obese may require 0.8-1.2 units/kg/day Type 2 diabetes mellitus Type 2 diabetes mellitus inadequately controlled with oral medication Adult: SC Usual range: 0.5-1 u/kg/day. Rapid-acting formulations, such as insulin lispro, given before meals with an intermediate- or long-acting insulin as a dose of 10 units/day SC (or 0.1-0.2 unit/kg/day) given at bedtime generally recommended Continuous SC injection (insulin pump) May be administered by continuous SC infusion in the abdominal wall Do not use diluted or mixed insulins in external insulin pumps Infusion sites should be rotated within the same region to reduce the risk of lipodystrophy Continuous subcutaneous infusion pump (i.e., insulin pump) not for Insulin Lispro U-200 administration;Insulin Lispro U-100 only Initial programming of the external insulin infusion pump should be based on the total daily insulin dose of the previous regimen Intravenous Administration Dilute Insulin Lispro U-100 to concentrations from 0.1 unit/mL to 1.0 unit/mL using 0.9% sodium chloride. Administer Insulin Lispro U-100 intravenously ONLY under medical supervision with close monitoring of blood glucose and potassium levels to avoid hypoglycemia and hypokalemia Dosing Considerations When given subcutaneously, insulin lispro has a more rapid onset of action and a shorter duration of action than regular human insulin Dosage must be individualized; blood glucose monitoring is essential in all patients receiving insulin therapy Insulin requirements may be altered during stress, major illness, or with changes in exercise, meal patterns, or coadministered drugs

Type I Diabetes Mellitus Rapid-acting human insulin analogue indicated to improve glycemic control in adults and children with diabetes mellitus <3 years: Safety and efficacy not established >3 years: May require 0.8-1.2 units/kg/day SC during growth spurts; otherwise, use adult dosing (0.5-1 unit/kg/day)

Renal impairment: Dose reduction may be needed.

Hypoglycaemia.Hypersensitivity to any of the components.

Insulin lispro, a rapid-acting analog of human insulin, lowers blood glucose levels. It regulates carbohydrate, protein and fat metabolism by inhibiting hepatic glucose production and lipolysis, and enhancing peripheral glucose disposal.

Renal or hepatic impairment; pregnancy, lactation; transferring from other insulin. Monitor serum glucose, potassium, electrolytes, HbA1c and lipid profile. Concomitant illness esp infections. Lactation: Considered safe for use during breastfeeding

Hypoglycaemia; hypokalemia, oedema; pruritus; pulpitation, nausea, rash; hypersensitivity reactions; lipoatropy or lipohypertrophy with SC Inj.

Effects may be increased by: oral antidiabetic agents, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics. Effects may be decreased by: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, oral contraceptives, lithium. Signs of hypoglycaemia may be masked by beta-blockers, clonidine.